Incannex Healthcare Inc. IQI0.SG Stock
Incannex Healthcare Inc. Price Chart
Incannex Healthcare Inc. IQI0.SG Financial and Trading Overview
Incannex Healthcare Inc. stock price | 0.71 EUR |
Previous Close | 1.57 EUR |
Open | 1.56 EUR |
Bid | 1.56 EUR x N/A |
Ask | 1.88 EUR x N/A |
Day's Range | 1.56 - 1.56 EUR |
52 Week Range | 1.45 - 5.45 EUR |
Volume | 0 EUR |
Avg. Volume | 32 EUR |
Market Cap | 104.24M EUR |
Beta (5Y Monthly) | 1.70498 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
IQI0.SG Valuation Measures
Enterprise Value | 71.8M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 133.23735 |
Price/Book (mrq) | 1.0576271 |
Enterprise Value/Revenue | 91.775 |
Enterprise Value/EBITDA | N/A |
Trading Information
Incannex Healthcare Inc. Stock Price History
Beta (5Y Monthly) | 1.70498 |
52-Week Change | -65.023% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.45 EUR |
52 Week Low | 1.45 EUR |
50-Day Moving Average | 1.66 EUR |
200-Day Moving Average | 2.87 EUR |
IQI0.SG Share Statistics
Avg. Volume (3 month) | 32 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 63.48M |
Float | 50.66M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.079% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1958.034% |
Gross Margin | 121.46% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -16.61% |
Return on Equity (ttm) | -32.081% |
Income Statement
Revenue (ttm) | 782.38K EUR |
Revenue Per Share (ttm) | 0.03 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 776.05K EUR |
EBITDA | N/A |
Net Income Avi to Common (ttm) | -18188050 EUR |
Diluted EPS (ttm) | -16.4 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 41.42M EUR |
Total Cash Per Share (mrq) | 0.65 EUR |
Total Debt (mrq) | 231.99K EUR |
Total Debt/Equity (mrq) | 0.25 EUR |
Current Ratio (mrq) | 37.632 |
Book Value Per Share (mrq) | 1.475 |
Cash Flow Statement
Operating Cash Flow (ttm) | -15554722 EUR |
Levered Free Cash Flow (ttm) | -6570526 EUR |
Profile of Incannex Healthcare Inc.
Country | Germany |
State | NSW |
City | Sydney |
Address | 105/8 Century Circuit |
ZIP | 2153 |
Phone | N/A |
Website | https://www.incannex.com.au |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.
Q&A For Incannex Healthcare Inc. Stock
What is a current IQI0.SG stock price?
Incannex Healthcare Inc. IQI0.SG stock price today per share is 0.71 EUR.
How to purchase Incannex Healthcare Inc. stock?
You can buy IQI0.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Incannex Healthcare Inc.?
The stock symbol or ticker of Incannex Healthcare Inc. is IQI0.SG.
Which industry does the Incannex Healthcare Inc. company belong to?
The Incannex Healthcare Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Incannex Healthcare Inc. have in circulation?
The max supply of Incannex Healthcare Inc. shares is 92.68M.
What is Incannex Healthcare Inc. Price to Earnings Ratio (PE Ratio)?
Incannex Healthcare Inc. PE Ratio is 0.00000000 now.
What was Incannex Healthcare Inc. earnings per share over the trailing 12 months (TTM)?
Incannex Healthcare Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Incannex Healthcare Inc. company belong to?
The Incannex Healthcare Inc. sector is Healthcare.